ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma

ClinicalTrials.gov ID: NCT01514188

Public ClinicalTrials.gov record NCT01514188. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 14, 2026, 7:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) Compared to Doxorubicin in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma

Study identification

NCT ID
NCT01514188
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
ImmunityBio, Inc.
Industry
Enrollment
126 participants

Conditions and interventions

Eligibility (public fields only)

Age range
15 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 10, 2012
Primary completion
Apr 8, 2014
Completion
Dec 14, 2014
Last update posted
May 28, 2024

2012 – 2014

United States locations

U.S. sites
5
U.S. states
4
U.S. cities
5
Facility City State ZIP Site status
Sarcoma Oncology Center Santa Monica California 90403
Stanford University Stanford California 94305
University of Iowa Iowa City Iowa 52242
Pennsylvania Hematology Oncology Associates Philadelphia Pennsylvania 19106
CTRC Institute for Drug Development, University of Texas San Antonio Texas 78229-3900

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 29 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01514188, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 28, 2024 · Synced May 14, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01514188 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →